儿童肝移植受者舌下给予他克莫司的群体药代动力学
本研究在26例因胆道闭锁行肝移植的患儿中建立舌下给予他克莫司的群体药代动力学模型,发现清除率随移植后时间变化,镇静状态影响吸收速率与生物利用度,模型可解释非镇静患者的肠道与肝脏首过吸收特征。
要点
- 移植后4.6天清除率达最大消除能力一半(CLMAX=4.1 L/h)。
- 非镇静患者吸收速率常数高于镇静者(1.1 vs 0.1 h⁻¹)。
- 非镇静患者移植后14天生物利用度降低24%。
核心结论
- 建立了儿童肝移植受者舌下给予他克莫司的群体药代动力学模型,可区分不同吸收机制。
- 模型外部验证后,移植后时间对清除率的影响及镇静状态可考虑用于常规剂量管理。
研究设计与样本
- 回顾性群体药代动力学研究,纳入2016至2021年间26例因胆道闭锁行肝移植的患儿。
- 记录人口学、临床和药理变量,包括治疗药物监测的全血浓度及密集采样药代动力学数据。
- 使用NONMEM v7.4进行群体药代动力学分析。
主要发现
- 他克莫司处置最佳拟合为二室模型,清除率在移植后4.6天达最大消除能力一半(CLMAX=4.1 L/h)。
- 非镇静状态较镇静状态一级吸收速率常数增加(1.1 vs 0.1 h⁻¹),移植后14天生物利用度降低24%。
- 模型以肠道生物利用度(0.9)和肝脏提取率解释非镇静患者口服吸收模式,后者负责首过效应。
- 个体间变异为中等(肠道生物利用度25.9%)至高(中央室表观分布容积79.8%,T50为101%)。
临床怎么用
- 模型外部验证后,常规剂量管理可考虑移植后时间对清除率的影响及镇静状态。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Pharmacokinetics of tacrolimus after sublingual administration is not characterized in paediatric liver transplant patients. Therefore, we aimed to develop a population pharmacokinetic model of sublingually administered tacrolimus in patients who cannot swallow the capsules due to their age, sedation status and/or mechanical ventilation during the first weeks post-transplantation. METHODS: Demographic, clinical and pharmacological variables, including tacrolimus whole blood concentrations obtained from therapeutic drug monitoring and data from dense-sampling pharmacokinetic profiles, were recorded in 26 paediatric patients with biliary atresia who underwent liver transplantation between 2016 and 2021. Population pharmacokinetic analysis was performed with NONMEM v7.4. RESULTS: Disposition of tacrolimus was best characterized by a 2-compartment model with clearance achieving half of the maximum elimination capacity (CLMAX = 4.1 L/h) at 4.6 days post-transplantation (T50 ). Compared to sedated patients, nonsedated status showed an increased first-order absorption rate constant (1.1 vs. 0.1 h-1 ) and a 24% reduction in bioavailability (FNS ) at 14 days post-transplant. The model was able to explain the oral absorption pattern in nonsedated patients as the result of gut bioavailability (0.9) and hepatic extraction ratio, with the latter being responsible for first-pass effects. Estimates of interindividual variability remained moderate (25.9% for the gut bioavailability) to high (79.8% for the apparent volume of distribution of the central compartment, and 101% for T50 ). CONCLUSION: A population pharmacokinetic model of sublingually administered tacrolimus in paediatric patients was developed to characterize different absorption mechanisms. Once the model is externally validated, the effect of post-transplant time on clearance and the sedation status may be considered in routine dosing management.
引用
- Riva N, Ibarra M, Parra-Guillen ZP, et al. Population pharmacokinetics of sublingually administered tacrolimus in infants and young children with liver transplantation. Br J Clin Pharmacol. 2022. PMID: 36222177. doi:10.1111/bcp.15563
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。